Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Mallya, Sharmila ^a   Fitch, Briana A ^a   Lee, J Scott ^a   So, Lomon ^a   Janes, Matthew R ^a   Fruman, David A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN 1; INITIATION FACTOR 4E BINDING PROTEIN 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; MLN 0128; RAPAMYCIN; UNCLASSIFIED DRUG; 3 (2 AMINO 5 BENZOXAZOLYL) 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 4 AMINE; BENZOXAZOLE DERIVATIVE; EIF4EBP1 PROTEIN, HUMAN; PHOSPHOPROTEIN; PYRIMIDINE DERIVATIVE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

4EBP1 GENE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GENE SILENCING; HUMAN; HUMAN CELL; LYMPHOMA; LYMPHOMA CELL; ONCOGENE; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; REGULATORY MECHANISM; ANTAGONISTS AND INHIBITORS; DEFICIENCY; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; BENZOXAZOLES; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE; GENE KNOCKDOWN TECHNIQUES; HUMANS; LYMPHOMA; PHOSPHOPROTEINS; PYRIMIDINES; TETRAZOLIUM SALTS; THIAZOLES; TOR SERINE-THREONINE KINASES;

EID: 84896138134     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088865     Document Type: Article

References (28)

1. Hagner PR, Schneider A, Gartenhaus RB (2010) Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood 115: 2127-2135.
2. Silvera D, Formenti SC, Schneider RJ (2010) Translational control in cancer. Nat Rev Cancer 10: 254-266.
3. Ruggero D, Montanaro L, Ma L, Xu W, Londei P, et al. (2004) The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 10: 484-486. (Pubitemid 38667906)
4. Malina A, Cencic R, Pelletier J (2011) Targeting translation dependence in cancer. Oncotarget 2: 76-88.
5. Laplante M, Sabatini DM (2012) mTOR Signaling in Growth Control and Disease. Cell 149: 274-293.
6. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N (2006) mTOR signaling: implications for cancer and anticancer therapy. Brit J Cancer 94: 195-199. (Pubitemid 43151534)
7. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124: 471-484. (Pubitemid 43199434)
8. Vu C, Fruman DA (2010) Target of rapamycin signaling in leukemia and lymphoma. Clin Cancer Res 16: 5374-5380.
9. Sonenberg N, Hinnebusch AG (2009) Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136: 731-745.
10. Guertin DA, Sabatini DM (2009) The pharmacology of mTOR inhibition. Sci Signal 2: pe24.
11. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J (2008) Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A 105: 17414-17419.
12. Benjamin D, Colombi M, Moroni C, Hall MN (2011) Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discovery 10: 868-880.
13. Feldman ME, Shokat KM (2010) New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs). Curr Top Microbiol Immunol 347: 241-262.
14. Wander SA, Hennessy BT, Slingerland JM (2011) Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 121: 1231-1241.
15. Alain T, Sonenberg N, Topisirovic I (2012) mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio. Oncotarget 3: 1491-1492.
16. Martineau Y, Azar R, Muller D, Lasfargues C, El Khawand S, et al. (2013) Pancreatic tumours escape from translational control through 4E-BP1 loss. Oncogene 2013; PMID:23563181; http://dx.doi.org/10.1038/onc.2013.100.
17. Foon KA, Takeshita K, Zinzani PL (2012) Novel therapies for aggressive B-cell lymphoma. Adv Hematol 2012: 302570.
18. Janes MR, Limon JJ, So L, Chen J, Lim RJ, et al. (2010) Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 16: 205-213.
19. Janes MR, Vu C, Mallya S, Shieh MP, Limon JJ, et al. (2013) Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia 27: 586-594.
20. Bhende PM, Park SI, Lim MS, Dittmer DP, Damania B (2010) The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia 24: 1781-1784.
21. Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, et al. (2009) Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 114: 2926-2935.
22. Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, et al. (2011) CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117: 591-594.
23. Garcia-Garcia C, Ibrahim YH, Serra V, Calvo MT, Guzman M, et al. (2012) Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy. Clin Cancer Res 18: 2603-2612.
24. Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, et al. (2012) The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 485: 55-61.
25. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, et al. (2013) Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2013. PMID:23542178 doi:10.1038/onc.2013.92.
26. Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, et al. (2006) Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 203: 311-317. (Pubitemid 43290840)
27. Avdulov S, Li S, Michalek V, Burrichter D, Peterson M, et al. (2004) Activation of translation complex eIF4F is essential for the genesis and maintenance of the malignant phenotype in human mammary epithelial cells. Cancer Cell 5: 553-563. (Pubitemid 38748917)
28. Jang GM, Leong LE, Hoang LT, Wang PH, Gutman GA, et al. (2004) Structurally distinct elements mediate internal ribosome entry within the 5′-noncoding region of a voltage-gated potassium channel mRNA. J Biol Chem 279: 47419-47430. (Pubitemid 39540884)